January 18, 2024
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of non-small cell lung cancer (NSCLC), following progression on or after platinum-based therapy, has been accepted… Read More
learn more
January 9, 2024
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
Final data from the TRIDENT trial anticipated in 2026 ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the global phase 3 TRIDENT clinical trial evaluating the safety and efficacy of initiating Optune Gio® (formerly known as Optune®) concurrent with… Read More
learn more
January 8, 2024
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
Preliminary full year 2023 net revenues of $509 million and fourth quarter net revenues of $134 million PMA application for TTFields in NSCLC submitted for review to U.S. Food and Drug Administration Nicholas Leupin M.D., Ph.D. appointed as Novocure Chief Medical Officer, effective January 1, 2024 Novocure to present at… Read More
learn more
January 4, 2024
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced the appointment of Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical Officer. Dr. Leupin brings a proven track record of leadership and accomplishment in the biotechnology and pharmaceutical industries, as well as extensive experience as a medical oncologist… Read More
learn more
